Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S, Kawakami H, Shiraishi O, Kanemura H, Suzuki S, Haratani K, Hayashi H, Yonesaka K, Chiba Y, Yasuda T, Nakagawa K. Mitani S, et al. Among authors: haratani k. Esophagus. 2023 Apr;20(2):290. doi: 10.1007/s10388-023-00986-1. Esophagus. 2023. PMID: 36658273 No abstract available.
LIS1 and NDEL1 coordinate the plus-end-directed transport of cytoplasmic dynein.
Yamada M, Toba S, Yoshida Y, Haratani K, Mori D, Yano Y, Mimori-Kiyosue Y, Nakamura T, Itoh K, Fushiki S, Setou M, Wynshaw-Boris A, Torisawa T, Toyoshima YY, Hirotsune S. Yamada M, et al. Among authors: haratani k. EMBO J. 2008 Oct 8;27(19):2471-83. doi: 10.1038/emboj.2008.182. Epub 2008 Sep 11. EMBO J. 2008. PMID: 18784752 Free PMC article.
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J. Nonagase Y, et al. Among authors: haratani k. Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743. Oncotarget. 2016. PMID: 27768588 Free PMC article.
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K. Shimizu T, et al. Among authors: haratani k. Cancer Chemother Pharmacol. 2017 Mar;79(3):489-495. doi: 10.1007/s00280-016-3231-3. Epub 2017 Jan 31. Cancer Chemother Pharmacol. 2017. PMID: 28144730 Free PMC article. Clinical Trial.
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. Haratani K, et al. Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183. Ann Oncol. 2017. PMID: 28407039 Free article.
62 results